Larimar Therapeutics, Inc. (LRMR) Research

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.

Market snapshot

Symbol
LRMR
Price
$3.64
Day change
+2.82%
Market cap
$311.5M
P/E ratio
-1.87x
52-week range
2.22-6.42
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$12.00

Peer companies

  • AC Immune S.A. (ACIU)
  • Altimmune, Inc. (ALT)
  • Amarin Corporation plc (AMRN)
  • Annexon, Inc. (ANNX)
  • Alto Neuroscience, Inc. (ANRO)
  • DBV Technologies S.A. (DBVT)
  • enGene Holdings Inc. (ENGN)
  • Korro Bio, Inc. (KRRO)

Recent insider activity

  • Flynn James E — A-Award (55150 shares) on 2026-05-19
  • LEFF JONATHAN S — A-Award (55150 shares) on 2026-05-19
  • SHERMAN JEFFREY W — A-Award (55150 shares) on 2026-05-19
  • Truitt Joseph — A-Award (55150 shares) on 2026-05-19
  • THOMAS FRANK E — A-Award (55150 shares) on 2026-05-19

Open Larimar Therapeutics, Inc. (LRMR) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.